Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dyspnoea, Fatigue, Heart rate increased, Hypertension
Clinical narrative: shortness of breath; loss of energy; high blood pressure; Heart rate >100 beats per min; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (shortness of breath), ASTHENIA (loss of energy), HYPERTENSION (high blood pressure), HEART RATE INCREASED (Heart rate >100 beats per min) and FATIGUE (Tiredness) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 004H20) for COVID-19 vaccination.     Concomitant products included CALCIUM MEFOLINATE, PYRIDOXINE HYDROCHLORIDE, VITAMIN B12 NOS (METANX) for Folic acid supplementation, ACETYLSALICYLIC ACID (BABY ASPIRIN), ATORVASTATIN and MULTIVITAMINS & MINERALS PLUS LUTEIN for an unknown indication.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (shortness of breath), ASTHENIA (loss of energy), HYPERTENSION (high blood pressure), HEART RATE INCREASED (Heart rate >100 beats per min) and FATIGUE (Tiredness). The patient was treated with AMLODIPINE (oral) for Hypertension, at a dose of 5 mg. At the time of the report, DYSPNOEA (shortness of breath), ASTHENIA (loss of energy) and HYPERTENSION (high blood pressure) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   for Treatment Amlodipine 5 mg for Blood pressure is used Concomitant Medicine: Baby aspirin, Metanx (folic acid), atorvastatin, and bunch of vitamins   Most recent FOLLOW-UP information incorporated above includes: On 21-Jul-2021: Significant follow up with Vaccine Hypersensitivity Form: Events outcome: ongoing events & new events added. Patient demographic information added This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (shortness of breath), ASTHENIA (loss of energy), HYPERTENSION (high blood pressure), HEART RATE INCREASED (Heart rate >100 beats per min) and FATIGUE (Tiredness) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 004H20) for COVID-19 vaccination.     Concomitant products included CALCIUM MEFOLINATE, PYRIDOXINE HYDROCHLORIDE, VITAMIN B12 NOS (METANX) for Folic acid supplementation, ACETYLSALICYLIC ACID (BABY ASPIRIN), ATORVASTATIN and MULTIVITAMINS & MINERALS PLUS LUTEIN for an unknown indication.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (shortness of breath), ASTHENIA (loss of energy), HYPERTENSION (high blood pressure), HEART RATE INCREASED (Heart rate >100 beats per min) and FATIGUE (Tiredness). The patient was treated with AMLODIPINE (oral) for Hypertension, at a dose of 5 mg. At the time of the report, DYSPNOEA (shortness of breath), ASTHENIA (loss of energy) and HYPERTENSION (high blood pressure) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   the blood pressure was measured during treatment was found to be according to months mar-2021:180/88,apr-2021:166/77,may-2021:152/78,jun-2021:144/75,July-2021:130/70 patient history was not found by reporter Concomitant products included CALCIUM MEFOLINATE, PYRIDOXINE HYDROCHLORIDE, VITAMIN B12 NOS (METANX) for Folic acid supplementation, ACETYLSALICYLIC ACID (BABY ASPIRIN), ATORVASTATIN and MULTIVITAMINS & MINERALS PLUS LUTEIN for an unknown indication.   Most recent FOLLOW-UP information incorporated above includes: On 21-Jul-2021: Significant follow up with Vaccine Hypersensitivity Form: Events outcome: ongoing events & new events added. Patient demographic information added